http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 17:57:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+22++Filed+by%3A+Lundgren+Erik/26585358.html si-local-file:///var/storage/secattach/20260601/26585358.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+22++Filed+by%3A+Lundgren+Erik/26585358.html Mon, 01 Jun 2026 17:57:00 -0400 IMUX O.02321652 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+22++Filed+by%3A+Lundgren+Erik/26585358.html si-local-file:///var/storage/secattach/20260601/26585358.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+22++Filed+by%3A+Lundgren+Erik/26585358.html Mon, 01 Jun 2026 17:57:00 -0400 IMUX O.02321652 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+01++Filed+by%3A+Lundgren+Erik/26585352.html si-local-file:///var/storage/secattach/20260601/26585352.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+01++Filed+by%3A+Lundgren+Erik/26585352.html Mon, 01 Jun 2026 17:56:00 -0400 IMUX O.02321652 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+01++Filed+by%3A+Lundgren+Erik/26585352.html si-local-file:///var/storage/secattach/20260601/26585352.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+01++Filed+by%3A+Lundgren+Erik/26585352.html Mon, 01 Jun 2026 17:56:00 -0400 IMUX O.02321652 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+29/26575819.html si-local-file:///var/storage/secattach/20260529/26575819.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+29/26575819.html Fri, 29 May 2026 16:33:00 -0400 IMUX O.02321652 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+29/26575819.html si-local-file:///var/storage/secattach/20260529/26575819.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++IMMUNIC%2C+INC.+++++++++++++For%3A+Jun+29/26575819.html Fri, 29 May 2026 16:33:00 -0400 IMUX O.02321652 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+28/26561003.html si-local-file:///var/storage/secattach/20260528/26561003.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+28/26561003.html Thu, 28 May 2026 07:01:00 -0400 IMUX O.02321652 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+28/26561003.html si-local-file:///var/storage/secattach/20260528/26561003.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IMMUNIC%2C+INC.+++++++++++++For%3A+May+28/26561003.html Thu, 28 May 2026 07:01:00 -0400 IMUX O.02321652 http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html <p>Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.</p> <p>A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html Thu, 28 May 2026 06:30:26 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html <p>Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.</p> <p>A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html Thu, 28 May 2026 06:30:26 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html <p>Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.</p> <p>A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html Thu, 28 May 2026 06:30:26 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html <p>Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.</p> <p>A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html Thu, 28 May 2026 06:30:26 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html <p>Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.</p> <p>A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html Thu, 28 May 2026 06:30:26 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html <p>Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.</p> <p>A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html Thu, 28 May 2026 06:30:26 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html <p>Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.</p> <p>A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html Thu, 28 May 2026 06:30:26 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html <p>Immunic Inc. (NASDAQ: IMUX) announced the presentation of additional data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium in patients with progressive multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis that introduced a unified statistical approach called Confirmed Disability Change (CDC) designed to capture both disability worsening and improvement within a single framework. The analysis applied three statistical models to CALLIPER trial data, with results consistently favoring vidofludimus calcium over placebo.</p> <p>A second poster examined patient-reported outcomes from the trial, including measures of depressive thoughts http://www.streetinsider.com/FDA/Immunic+presents+additional+data+on+multiple+sclerosis+drug+candidate/26560756.html Thu, 28 May 2026 06:30:26 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html <p>Immunic Inc. (NASDAQ: IMUX) presented additional data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis introducing a unified statistical approach called Confirmed Disability Change that measures both disability worsening and improvement. The analysis applied three statistical models to CALLIPER trial data, with results favoring vidofludimus calcium over placebo across all approaches.</p> <p>Patient-reported outcomes data showed PHQ-9 depression scores improved numerically in both treatment groups through 120 weeks, with no indication of worsening depressive thoughts with vidofludimus http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html Thu, 28 May 2026 06:30:25 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html <p>Immunic Inc. (NASDAQ: IMUX) presented additional data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis introducing a unified statistical approach called Confirmed Disability Change that measures both disability worsening and improvement. The analysis applied three statistical models to CALLIPER trial data, with results favoring vidofludimus calcium over placebo across all approaches.</p> <p>Patient-reported outcomes data showed PHQ-9 depression scores improved numerically in both treatment groups through 120 weeks, with no indication of worsening depressive thoughts with vidofludimus http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html Thu, 28 May 2026 06:30:25 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html <p>Immunic Inc. (NASDAQ: IMUX) presented additional data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis introducing a unified statistical approach called Confirmed Disability Change that measures both disability worsening and improvement. The analysis applied three statistical models to CALLIPER trial data, with results favoring vidofludimus calcium over placebo across all approaches.</p> <p>Patient-reported outcomes data showed PHQ-9 depression scores improved numerically in both treatment groups through 120 weeks, with no indication of worsening depressive thoughts with vidofludimus http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html Thu, 28 May 2026 06:30:25 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html <p>Immunic Inc. (NASDAQ: IMUX) presented additional data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis introducing a unified statistical approach called Confirmed Disability Change that measures both disability worsening and improvement. The analysis applied three statistical models to CALLIPER trial data, with results favoring vidofludimus calcium over placebo across all approaches.</p> <p>Patient-reported outcomes data showed PHQ-9 depression scores improved numerically in both treatment groups through 120 weeks, with no indication of worsening depressive thoughts with vidofludimus http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html Thu, 28 May 2026 06:30:25 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html <p>Immunic Inc. (NASDAQ: IMUX) presented additional data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis introducing a unified statistical approach called Confirmed Disability Change that measures both disability worsening and improvement. The analysis applied three statistical models to CALLIPER trial data, with results favoring vidofludimus calcium over placebo across all approaches.</p> <p>Patient-reported outcomes data showed PHQ-9 depression scores improved numerically in both treatment groups through 120 weeks, with no indication of worsening depressive thoughts with vidofludimus http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html Thu, 28 May 2026 06:30:25 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html <p>Immunic Inc. (NASDAQ: IMUX) presented additional data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis introducing a unified statistical approach called Confirmed Disability Change that measures both disability worsening and improvement. The analysis applied three statistical models to CALLIPER trial data, with results favoring vidofludimus calcium over placebo across all approaches.</p> <p>Patient-reported outcomes data showed PHQ-9 depression scores improved numerically in both treatment groups through 120 weeks, with no indication of worsening depressive thoughts with vidofludimus http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html Thu, 28 May 2026 06:30:25 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html <p>Immunic Inc. (NASDAQ: IMUX) presented additional data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis introducing a unified statistical approach called Confirmed Disability Change that measures both disability worsening and improvement. The analysis applied three statistical models to CALLIPER trial data, with results favoring vidofludimus calcium over placebo across all approaches.</p> <p>Patient-reported outcomes data showed PHQ-9 depression scores improved numerically in both treatment groups through 120 weeks, with no indication of worsening depressive thoughts with vidofludimus http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html Thu, 28 May 2026 06:30:25 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html <p>Immunic Inc. (NASDAQ: IMUX) presented additional data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, NC.</p> <p>The company presented three posters, including a late-breaking analysis introducing a unified statistical approach called Confirmed Disability Change that measures both disability worsening and improvement. The analysis applied three statistical models to CALLIPER trial data, with results favoring vidofludimus calcium over placebo across all approaches.</p> <p>Patient-reported outcomes data showed PHQ-9 depression scores improved numerically in both treatment groups through 120 weeks, with no indication of worsening depressive thoughts with vidofludimus http://www.streetinsider.com/FDA/Immunic+presents+phase+2+trial+data+at+multiple+sclerosis+meeting/26560754.html Thu, 28 May 2026 06:30:25 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449 http://www.streetinsider.com/Press+Releases/Immunic+to+Present+Additional+Phase+2+CALLIPER+Trial+Data+for+Vidofludimus+Calcium+at+the+CMSC+Annual+Meeting+2026%2C+Reinforcing+Its+Potential+in+Progressive+Multiple+Sclerosis/26560748.html <div class="xn-content"> <p class="prntac"><i>– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis –</i></p><p class="prntac"><i>– Additional CALLIPER Data Further Highlight Vidofludimus Calcium's Favorable Safety and Tolerability Profile; Patient-Reported Outcomes Assessments Show No Negative Impact on Mood –</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4697603-1&amp;h=1214841930&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:IMUX" idsrc="xmltag.org" >Immunic</span></b><b>, Inc.</b></a><b> </b>(Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the presentation of one late-breaking and two additional posters highlighting additional data from its phase 2 CALLIPER trial http://www.streetinsider.com/Press+Releases/Immunic+to+Present+Additional+Phase+2+CALLIPER+Trial+Data+for+Vidofludimus+Calcium+at+the+CMSC+Annual+Meeting+2026%2C+Reinforcing+Its+Potential+in+Progressive+Multiple+Sclerosis/26560748.html Thu, 28 May 2026 06:30:00 -0400 A.13662202 A.14320728 A.60012014 IMUX O.00063751 O.02321652 O.20250741 O.21652449